SMS Pharmaceuticals share news, announcements and annual reports
NSE: SMSPHARMABSE: 532815Pharmaceuticals & BiotechnologySmall Cap
SMS Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2007
Last close ₹504.15down ₹7.20 (1.41%)BSE ₹504.25
Share price at the NSE close on 2 Nov 2026. Previous close ₹511.35.
2 Nov: open ₹511.00, high ₹514.80, low ₹471.25
52-week range of traded prices to 2 Nov 2026
₹270.10Low, 24 Nov 2025₹525.00High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,721 Cr920th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 45.98
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.01
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.46
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,24,26833.2% delivered
SMS Pharmaceuticals share news and announcements
718 announcements, routine notices left out, newest first. Page 15 of 15.
Oct 2007
30 Oct · Utilisation of Funds
Details of Projected Vs Actual Depolyment of Funds. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Oct · Utilisation of Funds
Vide notes to Unaudited Financial Results for the quarter ended September 30, 2007 (taken on record by the Board of the directors of the Company at its Meeting held on October 29, 2007) regarding the amount spent out of the funds raised, by IPO and other sources, during the previous year. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Oct · Business
In the Board Meeting held on October 29, 2007 the Board has taken the following decisions :- 1) Considered for the merger of Sreenivasa Pharma Private Limited (wholly owned subsidiary) with the company.23 Oct · Meeting
Minutes of Annual General Meeting of the Company held on September 28, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Oct · Board meeting
Meeting on 29 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Sep 2007
28 Sep · Meeting
Members at the Annual General Meeting of the Company held on September 28, 2007, inter alia, have accorded the followings :- 1) Declaration of Dividend of Rs. 2.00 per equity share or 20% on equity shares of Rs. 10/- each, for the year ended March 31, 2007. 2) Re-appointment of Dr. Mihir K. Chaudhuri, Dr. B. M. Choudary and appointment of Mr. Abdul Razzaq Yousef as Directors of the Company. 3) Appointment of M/s. Rambabu & Co., Chartered Accountants and M/s. P. Murali & Co., Chartered Accountants as Joint Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting of the Company.24 Sep · Miscellaneous
The Board of SMS Pharmaceuticals Limited has decided to take over and revive a BIFR Company M/s. Plant Organics Limited with whom we already have job work arrangement. This will add to our product range and manufacturing facility along with substantial tax benefits. The plant is situated very close to our existing Manufacturing Facilities
Aug 2007
28 Aug · Meeting
In the Board Meeting of the company held on August 27, 2007, the Board has taken the following decisions:- 1) Recommended 20% dividend on the paid up share capital of the Company for the year 2006-07. 2) Annual General Meeting of the Company will be held on September 28, 2007. 3) The register of members and the share transfer books of the Company will remain closed from September 25, 2007 to September 28, 2007(both days inclusive).20 Aug · Board meeting
To consider the followings : 1) To consider and approve the Audited Annual Accounts for the year ended on March 31, 2007 ; 2) To consider the payment of dividend for the year 2006-07 if any ; 3) To fix the date of Annual General Meeting of the Company ; 4) To consider any other matter with the permission of the Chair.
Jul 2007
31 Jul · Utilisation of Funds
Details of amount spent out of the funds raised, by IPO and other sources, during the previous year. The detail of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Jul · Utilisation of Funds
Statement showing the details of Projected Vs. Actual Deployment of Funds for the quarter ended on June 30, 2007. The details of the statement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jul · Board meeting
In our Board Meeting held on 30.07.2007 the Board has taken the following decisions :- 1) Considered and approved the Un-audited Financial Results for the quarter ended on 30th June, 2007. 2) Appointment of Mr. Abdul Razzaq Yousef, CEO of Gulf Pharmaceutical Industries, U.A.E. as Additional Director in the Board of Directors of the Company. Mr. Abdul Razzaq Yousef, is aged about 40 years and he did his master degree from University of Miami, USA. He joined in Gulf Pharmaceuticals in the year 1986 and had been associated with the Company till date. He has vast Experience in the area of Strategy Formulations, Project Planning and Development. His other directorships are 1) Consulting Engineering group, UAE, RAK. 2) Gulf Pharmaceutical Industries, UAE. As you are aware that Gulf Pharmaceutical Industries has 9% Equity Shares in our Company18 Jul · Board meeting
Meeting on 30 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
May 2007
28 May · E-mail ID for Investor Complaints
We have created an exclusive Email ID namely : cs@smspharma.com to deal with the Investor Grievance Redressal8 May · Miscellaneous
Statement showing the details of Projected Vs. Actual Deployment of Funds for the quarter ended on March 31, 2007. The details of the statement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
30 Apr · Utilisation of Funds
Details of utilisation of funds received from the follow on Public Offer and pre IPO placement of equity shares and term Loan disbursement availed. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Apr · Board meeting
Interalia, to consider the un-audited financial results of the company for the quarter ended on March 31, 2007.
Mar 2007
30 Mar · Management
In our Board Meeting held on 28.03.2007 the board has taken the following decisions :- (1) Mr. R. Srinivasa Rao has been appointed as Company Secretary and Compliance Officer of the Company with effect from 23.03.2007 in place of Mr. G. Someswara Rao who has resigned as Company Secretary. (2) Entering the Memorandum of Understanding with Plant Organics Limited to entrust the job work for conversion of intermediates and other active pharma ingredients.